Stocks-CVAC-CureVac NV

CVAC CureVac NV

7.20 -0.26 (-3.49%)
in USD Market Open
Invest
-10.49% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
1.4B
Day’s Range
7.15
-
7.40
52W Range
6.89
-
49.95
Volume (3M)
334.32K
Price-Earnings Ratio
-
Revenue
107.19M
Top Discussions
MarketUpdates
$CVAC (CureVac NV) Q3 2022 earnings report is expected to be released
16
NOV
REPORTS
CureVac NV Q3 2022 earnings report released before market open
CVAC
CVAC
CureVac NV
7.20
-0.26
(-3.49%)
Trade
MarketUpdates
Edited
$CVAC (CureVac NV) Q3 2022 earnings report is expected to be released
CVAC
CureVac NV
7.20
-0.26 (-3.49%)
Trade
MarketUpdates
Edited
$CVAC (CureVac NV) Q3 2022 earnings report is expected to be released
CVAC
CureVac NV
7.20
-0.26 (-3.49%)
Trade
MarketUpdates
$CVAC (CureVac NV) Q3 2022 earnings report is expected to be released
Christian Rauchenwald
🔴 Yesterday's 𝗯𝗶𝗴𝗴𝗲𝘀𝘁 𝗹𝗼𝘀𝗲𝗿𝘀 $LAZR (Luminar Technologies Inc.) $ATNX (Athenex Inc) $CVAC (CureVac NV) $SFIX (Stitch Fix Inc) $NVAX (Novavax Inc) 🔴 NASDAQ YTD-Performance: -𝟯𝟬.𝟭𝟬% 🟢 My YTD-Performance: +𝟯𝟯.𝟯𝟰% 🟢 2021 +𝟯𝟰.𝟳𝟴% 🟢 2020 +𝟮𝟵.𝟴𝟬% 📌 Want to learn more... Show More

About CureVac NV

CureVac N.V. is a biopharmaceutical company founded in 2002 and headquartered in Tübingen, Germany. The firm is engaged in the development of therapies and vaccines based on messenger RNA (mRNA). Serving a worldwide audience, the company's primary focus is on developing vaccines for infectious diseases and drugs for the treatment of various cancers and rare diseases. CureVac was the first company in the world to successfully harness mRNA and use it for medical purposes. The firm launched as a public company in August 2020 and is listed on the NASDAQ GM, trading under the ticker CVAC. In December 2020, the CVAC share price showed a 52-week low of $36.15 and a 52-week high of $106.68, with a market cap of $18.89bn. The CVAC stock value increased by almost 3.5x on the company’s first day of trading as a public company, possibly due to the high profile of some of the vaccines it has in the pipeline, including a COVID-19 vaccine in phase II of clinical trials, as well as several other important vaccines at either phase I or the pre-clinical stage. CureVac N.V. is involved in every step of mRNA therapeutics development, from discovery to production. The company holds around 700 granted patents. Add CVAC stock to your eToro portfolio today and start tracking price movements and news updates.
884
Employees
Tübingen, Baden Wuerttemberg, US
HQ
2000
Founded
Franz-Werner Haas, PhD, LLD
CEO
Show More

People Also Bought